Plato Investment Management Ltd Has $9.49 Million Stock Position in Merck & Co., Inc. $MRK

Key Points

• Plato Investment Management increased its Merck stake by 15.3% in the second quarter, bringing its holdings to 74,299 shares valued at approximately $9.49 million. Institutional investors collectively own 76.07% of Merck’s stock.
• Merck shares rose 3.9% to $156.54, near their 52-week high, after the company exceeded quarterly earnings and revenue expectations. The company also declared a quarterly dividend of $0.85 per share, equivalent to a 2.2% annual yield.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $147.60, while several firms recently raised targets as high as $175. However, insiders sold nearly 228,238 shares worth about $30 million over the past three months.

Plato Investment Management Ltd increased its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 15.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,299 shares of the company's stock after acquiring an additional 9,877 shares during the period. Plato Investment Management Ltd's holdings in Merck & Co., Inc. were worth $9,492,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $3,997,933,000. Wellington Management Group LLP grew its stake in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after buying an additional 11,156,354 shares during the last quarter. Cardano Risk Management B.V. acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth $1,012,530,000. Jennison Associates LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $585,192,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Merck & Co., Inc. by 37.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company's stock valued at $1,973,983,000 after acquiring an additional 5,152,069 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Richard R. Deluca sold 20,784 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the sale, the executive vice president directly owned 134,703 shares of the company's stock, valued at $17,569,312.29. The trade was a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP David R. Maraldo sold 18,706 shares of the company's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. Trading Up 3.9%

Shares of Merck & Co., Inc. stock opened at $156.54 on Wednesday. The stock has a market capitalization of $386.22 billion, a PE ratio of 125.23, a price-to-earnings-growth ratio of 6.32 and a beta of 0.19. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92. The stock has a 50 day moving average price of $129.64 and a two-hundred day moving average price of $121.80. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the prior year, the firm earned $2.13 earnings per share. Merck & Co., Inc.'s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is 272.00%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on MRK shares. Scotiabank boosted their price target on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, June 30th. Cantor Fitzgerald reissued a "neutral" rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. UBS Group upped their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday, August 20th. BMO Capital Markets lifted their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a report on Thursday, August 20th. Finally, Weiss Ratings cut Merck & Co., Inc. from a "hold (c)" rating to a "hold (c-)" rating in a report on Tuesday, August 11th. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $147.60.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive topline INTerpath-001 results strengthened expectations that the vaccine could extend KEYTRUDA’s growth runway and create a potentially important new oncology franchise. Merck Surges on a Melanoma Win
• Positive Sentiment: Analysts raised their valuation expectations: Wolfe Research increased its price target to $180 and assigned an “outperform” rating, while Argus raised its target to $170 and reiterated a “buy” rating. Wolfe Research Price Target
• Positive Sentiment: Investors are also anticipating a concentrated series of regulatory decisions and clinical readouts this fall, which could produce additional upside if Merck’s pipeline delivers. What Would It Take to Get MRK Stock to $200?
• Neutral Sentiment: The cancer-vaccine opportunity remains early. The available evidence is limited, and potential barriers include manufacturing complexity, cost, patient selection, and the need for regulatory review and broader clinical validation. How the Merck/Moderna Cancer Vaccine Works
• Negative Sentiment: After the recent rally, MRK is trading near or above several analysts’ prior targets, leaving less room for disappointment and making future gains increasingly dependent on successful trial results, FDA decisions, and evidence that the post-KEYTRUDA growth strategy can scale.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source